PRPS2 Enhances Resistance to Cisplatin via Facilitating Exosomes-mediated Macrophage M2 Polarization in Non-small Cell Lung Cancer

References

• Becker M, Müller CB, De Bastiani MA, Klamt F. 2014. The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histol Histopathol. 29:21–31.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424.
   PubMed Web of Science ®Google Scholar
• Cunningham JT, Moreno MV, Lodi A, Ronen SM, Ruggero D. 2014. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell. 157:1088–103.
   PubMed Web of Science ®Google Scholar
• D’Antonio C, Milano A, Righini R, Onesti CE, Bassanelli M, Falcone R, Paris I, Lauro S, Marchetti P. 2014. Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. Anticancer Res. 34:5241–50.
   PubMed Web of Science ®Google Scholar
• Dong N, Shi X, Wang S, Gao Y, Kuang Z, Xie Q, Li Y, Deng H, Wu Y, Li M, et al. 2019. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer. 121:22–33.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. 2012. Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–83.
   PubMed Web of Science ®Google Scholar
• Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. 2015. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 15:577.
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. 2020. The biology, function, and biomedical applications of exosomes. Science. 367:eaau6977.
   PubMedGoogle Scholar
• Kelland L. 2007. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–84.
   PubMed Web of Science ®Google Scholar
• Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, et al. 2014. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. Int J Oncol. 45:1430–36.
   PubMed Web of Science ®Google Scholar
• Leung AW, De Silva T, Bally MB, Lockwood WW. 2016. Synthetic lethality in lung cancer and translation to clinical therapies. Mol Cancer. 15:61.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, et al. 2006. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 116:2132–41.
   PubMed Web of Science ®Google Scholar
• Maia J, Caja S, Strano Moraes MC, Couto N, Costa-Silva B. 2018. Exosome-based cell-cell communication in the tumor microenvironment. Front Cell Dev Biol. 6:18.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:549–55.
   PubMed Web of Science ®Google Scholar
• Martinez FO, Gordon S. 2014. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6:13.
   PubMedGoogle Scholar
• Martinez FO, Sica A, Mantovani A, Locati M. 2008. Macrophage activation and polarization. Front Biosci. 13:453–61.
   PubMed Web of Science ®Google Scholar
• Miao W, Wang Y. 2019. Targeted quantitative kinome analysis identifies PRPS2 as a promoter for colorectal cancer metastasis. J Proteome Res. 18:2279–86.
   PubMed Web of Science ®Google Scholar
• Murray PJ. 2017. Macrophage polarization. Annu Rev Physiol. 79:541–66.
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. 2014. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 41:49–61.
   PubMed Web of Science ®Google Scholar
• Qiao H, Tan X, Lv DJ, Xing RW, Shu FP, Zhong CF, Li C, Zou Y-G, Mao X-M. 2020. Phosphoribosyl pyrophosphate synthetases 2 knockdown inhibits prostate cancer progression by suppressing cell cycle and inducing cell apoptosis. J Cancer. 11:1027–37.
   PubMed Web of Science ®Google Scholar
• Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel L, Feuerhake F, Klaman I, et al. 2014. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 25:846–59.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98.
   PubMed Web of Science ®Google Scholar
• Sica A, Schioppa T, Mantovani A, Allavena P. 2006. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 42:717–27.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2017. Cancer statistics, 2017. CA Cancer J Clin. 67:7–30.
   PubMed Web of Science ®Google Scholar
• Solinas G, Germano G, Mantovani A, Allavena P. 2009. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 86:1065–73.
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yuan D, Bai Y, Pan Y, Zhang J, Shao C. 2020. Exosomes carrying ALDOA and ALDH3A1 from irradiated lung cancer cells enhance migration and invasion of recipients by accelerating glycolysis. Mol Cell Biochem. 469:77–87.
   Google Scholar
• Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, Tung Y-C, Hsu H-L. 2019. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 18:42.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. 2008. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 27:5904–12.
   PubMed Web of Science ®Google Scholar
• Xue C, Yu DM, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, et al. 2016. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. Oncotarget. 7:54937–51.
   PubMedGoogle Scholar
• Yu J-S, Jin J, Li -Y-Y. 2020. The Physiological functions of IKK-selective substrate identification and their critical roles in diseases. STEMedicine. 1:e49.
   Google Scholar
• Zappa C, Mousa SA. 2016. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 5:288–300.
   PubMed Web of Science ®Google Scholar